Skip to content
Catalyst

PapersPMID:40655486

Effects of spirulina supplementation alone or with exercise on cardiometabolic health in overweight and obese adults: a systematic review and meta-analysis.

Frontiers in nutrition2025The record ↗

findings
10
compound
1
endpoints
9
no difference found
4
PMID:40655486
  1. Finding, moderate evidencelowersTriglycerides
  2. Finding, moderate evidencelowersDiastolic blood pressure
  3. Finding, limited evidencelowersTotal cholesterol (TC)
  4. Finding, limited evidencelowersLDL cholesterol
  5. Finding, limited evidenceraisesHDL cholesterol
  6. Finding, limited evidencelowersBody mass
  7. Finding, moderate evidenceno difference foundBody mass
  8. Finding, moderate evidenceno difference foundBody mass index
  9. Finding, moderate evidenceno difference foundMaximal oxygen uptake
  10. Finding, moderate evidenceno difference foundFasting blood glucose
Study, every finding
meta-analysis
  • “Spirulina significantly lowered TC (N = 13, g = −0.79, 95% CI: −1.18 to −0.41, I2 = 76%, p < 0.01, low GRADE), TG (N = 13, g = −0.64, 95% CI: −1.00 to −0.28, I2 = 74%, p < 0.01, low GRADE), and LDL-C (N = 13, g = −0.71, 95% CI: −1.13 to −0.29, I2 = 80%, p < 0.01, moderate GRADE), while increasing HDL-C (N = 13, g = 0.53, 95% CI: 0.04 to 1.02, I2 = 86%, p = 0.03, very low GRADE).”
    • Decreases triglycerides

      moderatereplicated ×4

      Effect
      −0.64 standardised mean difference, 95% CI −1 to −0.28
      Dose studied
      0.02 to 10 g/day, 2 to 24 weeks, pooled
      Population
      Overweight or obese adults (BMI 25-40 kg/m2, aged 26-65 years) in the 21 trials (867 participants) of spirulina alone against placebo or no intervention; 13 trials contributed to this estimate
    • Effect
      −0.79 standardised mean difference, 95% CI −1.18 to −0.41
      Dose studied
      0.02 to 10 g/day, 2 to 24 weeks, pooled
      Population
      Overweight or obese adults (BMI 25-40 kg/m2, aged 26-65 years) in the 21 trials (867 participants) of spirulina alone against placebo or no intervention; 13 trials contributed to this estimate
    • Effect
      −0.71 standardised mean difference, 95% CI −1.13 to −0.29
      Dose studied
      0.02 to 10 g/day, 2 to 24 weeks, pooled
      Population
      Overweight or obese adults (BMI 25-40 kg/m2, aged 26-65 years) in the 21 trials (867 participants) of spirulina alone against placebo or no intervention; 13 trials contributed to this estimate
    • Effect
      0.53 standardised mean difference, 95% CI 0.04 to 1.02
      Dose studied
      0.02 to 10 g/day, 2 to 24 weeks, pooled
      Population
      Overweight or obese adults (BMI 25-40 kg/m2, aged 26-65 years) in the 21 trials (867 participants) of spirulina alone against placebo or no intervention; 13 trials contributed to this estimate
  • “Spirulina significantly reduced DBP (N = 4, g = −0.73, 95% CI: −1.43 to −0.03, I2 = 83%, p = 0.04, very low GRADE) and showed a trend toward reducing SBP (N = 4, g = −1.06, 95% CI: −2.23 to 0.10, I2 = 93%, p = 0.07, very low GRADE).”
    Effect
    −0.73 standardised mean difference, 95% CI −1.43 to −0.03
    Dose studied
    0.02 to 10 g/day, 2 to 24 weeks, pooled
    Population
    Overweight or obese adults (BMI 25-40 kg/m2, aged 26-65 years) in the 21 trials (867 participants) of spirulina alone against placebo or no intervention; four trials contributed to this estimate
  • “Spirulina significantly reduced BW compared to controls (N = 8, g = −0.30, 95% CI: −0.53 to −0.08, I2 = 15%, p < 0.01, low GRADE).”
    Effect
    −0.3 standardised mean difference, 95% CI −0.53 to −0.08
    Dose studied
    0.02 to 10 g/day, 2 to 24 weeks, pooled
    Population
    Overweight or obese adults (BMI 25-40 kg/m2, aged 26-65 years) in the 21 trials (867 participants) of spirulina alone against placebo or no intervention; eight trials contributed to this estimate

What did not

  • “Compared to placebo + exercise, Spirulina combined with exercise showed no significant effects on BW (N = 4, g = 0.01, 95% CI: −0.40 to 0.42, I2 = 0%, p = 0.95, low GRADE), BMI (N = 5, g = −0.54, 95% CI: −1.42 to 0.35, I2 = 79%, p = 0.24, very low GRADE), BFP (N = 4, g = −0.12, 95% CI: −0.52 to 0.28, I2 = 0%, p = 0.55, low GRADE), or VO2max (N = 3, g = 0.27, 95% CI: −0.20 to 0.74, I2 = 0%, p = 0.26, low GRADE).”
    • No detected effect on body mass

      moderatereplicated ×2

      Effect
      0.01 standardised mean difference, 95% CI −0.4 to 0.42
      Dose studied
      1 to 6 g/day, 4 to 12 weeks, pooled
      Population
      Overweight or obese adults (BMI 28-33 kg/m2, aged 21-62 years, no other comorbidities) in the 7 trials (168 participants) of spirulina plus exercise against placebo plus the same exercise; exercise is background in both arms; four trials contributed to this estimate
    • Effect
      −0.54 standardised mean difference, 95% CI −1.42 to 0.35
      Dose studied
      1 to 6 g/day, 4 to 12 weeks, pooled
      Population
      Overweight or obese adults (BMI 28-33 kg/m2, aged 21-62 years, no other comorbidities) in the 7 trials (168 participants) of spirulina plus exercise against placebo plus the same exercise; exercise is background in both arms; five trials contributed to this estimate
    • Effect
      0.27 standardised mean difference, 95% CI −0.2 to 0.74
      Dose studied
      1 to 6 g/day, 4 to 12 weeks, pooled
      Population
      Overweight or obese adults (BMI 28-33 kg/m2, aged 21-62 years, no other comorbidities) in the 7 trials (168 participants) of spirulina plus exercise against placebo plus the same exercise; exercise is background in both arms; three trials contributed to this estimate
  • “Spirulina showed no significant effect on FBG (N = 9, g = −0.26, 95% CI: −0.75 to 0.23, I2 = 80%, p = 0.29, very low GRADE) or INS (N = 4, g = −0.69, 95% CI: −1.62 to 0.24, I2 = 84%, p = 0.15, very low GRADE).”
    Effect
    −0.26 standardised mean difference, 95% CI −0.75 to 0.23
    Dose studied
    0.02 to 10 g/day, 2 to 24 weeks, pooled
    Population
    Overweight or obese adults (BMI 25-40 kg/m2, aged 26-65 years) in the 21 trials (867 participants) of spirulina alone against placebo or no intervention; nine trials contributed to this estimate

Study record

Design
meta-analysis
Species
human
Population
Overweight or obese adults (BMI > 25 kg/m2), some with type 2 diabetes, hypertension, metabolic syndrome, HIV on ART or ulcerative colitis
Participants
1,035
Comparator
placebo
Duration
not reported
Endpoints measured
46